Drosophila melanogaster as a Rapid and Reliable In Vivo Infection Model to Study the Emerging Yeast Pathogen Candida auris.
Antifungal treatment
Drosophila melanogaster
Fruit flies
Mini-host model
Pathogenicity
Virulence
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
8
6
2022
pubmed:
9
6
2022
medline:
11
6
2022
Statut:
ppublish
Résumé
While mammalian models remain the gold standard to study invasive mycoses, mini-host invertebrate models have provided complementary platforms for explorative investigations of fungal pathogenesis, host-pathogen interplay, and antifungal therapy. Specifically, our group has established Toll-deficient Drosophila melanogaster flies as a facile and cost-effective model organism to study candidiasis, and we have recently expanded these studies to the emerging and frequently multidrug-resistant yeast pathogen Candida auris. Our proof-of-concept data suggest that fruit flies could hold a great promise for large-scale applications in antifungal drug discovery and the screening of C. auris (mutant) libraries with disparate pathogenic capacity. This chapter discusses the advantages and limitations of D. melanogaster to study C. auris candidiasis and provides a step-by-step guide for establishing and troubleshooting C. auris infection and antifungal treatment of Toll-deficient flies along with essential downstream readouts.
Identifiants
pubmed: 35674964
doi: 10.1007/978-1-0716-2417-3_24
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
299-316Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Conti HR, Huppler AR, Whibley N et al (2014) Animal models for candidiasis. Curr Protoc Immunol 105:19.6.1–19.617
doi: 10.1002/0471142735.im1906s105
Segal E, Frenkel M (2018) Experimental in vivo models of candidiasis. J Fungi (Basel) 4(1):E21
doi: 10.3390/jof4010021
Muñoz JF, Gade L, Chow NA et al (2018) Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun 9(1):5346
doi: 10.1038/s41467-018-07779-6
Wall G, Chaturvedi AK, Wormley FL Jr et al (2018) Screening a repurposing library for inhibitors of multidrug-resistant Candida auris identifies ebselen as a repositionable candidate for antifungal drug development. Antimicrob Agents Chemother 62(10):e01084-18
doi: 10.1128/AAC.01084-18
O’Brien B, Chaturvedi S, Chaturvedi V (2020) In vitro evaluation of antifungal drug combinations against multidrug-resistant Candida auris isolates from New York outbreak. Antimicrob Agents Chemother 64(4):e02195-19
doi: 10.1128/AAC.02195-19
Wurster S, Kumaresan PR, Albert ND et al (2019) Live monitoring and analysis of fungal growth, viability, and mycelial morphology using the IncuCyte NeuroTrack processing module. mBio 10(3):e00673-19
doi: 10.1128/mBio.00673-19
Chamilos G, Lionakis MS, Lewis RE et al (2006) Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis 193(7):1014–1022
doi: 10.1086/500950
Chamilos G, Lewis RE, Hu J et al (2008) Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A 105(27):9367–9372
doi: 10.1073/pnas.0709578105
Hamilos G, Samonis G, Kontoyiannis DP (2012) Recent advances in the use of Drosophila melanogaster as a model to study immunopathogenesis of medically important filamentous fungi. Int J Microbiol 2012:583792
doi: 10.1155/2012/583792
Lionakis MS, Kontoyiannis DP (2012) Drosophila melanogaster as a model organism for invasive aspergillosis. Methods Mol Biol 845:455–468
doi: 10.1007/978-1-61779-539-8_32
Wurster S, Bandi A, Beyda ND et al (2019) Drosophila melanogaster as a model to study virulence and azole treatment of the emerging pathogen Candida auris. J Antimicrob Chemother 74(7):1904–1910
doi: 10.1093/jac/dkz100
Du H, Bing J, Hu T et al (2020) Candida auris: epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog 16(10):e1008921
doi: 10.1371/journal.ppat.1008921
Cortegiani A, Misseri G, Fasciana T et al (2018) Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care 6:69
doi: 10.1186/s40560-018-0342-4
Troha K, Buchon N (2019) Methods for the study of innate immunity in Drosophila melanogaster. Wiley Interdiscip Rev Dev Biol 8(5):e344
doi: 10.1002/wdev.344
Lionakis MS, Lewis RE, May GS et al (2005) Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis 191(7):1188–1195
doi: 10.1086/428587
Lionakis MS, Kontoyiannis DP (2010) The growing promise of Toll-deficient Drosophila melanogaster as a model for studying Aspergillus pathogenesis and treatment. Virulence 1(6):488–499
doi: 10.4161/viru.1.6.13311
Rowley AF, Powell A (2007) Invertebrate immune systems specific, quasi-specific, or nonspecific? J Immunol 179(11):7209–7214
doi: 10.4049/jimmunol.179.11.7209
Govind S (2008) Innate immunity in Drosophila: pathogens and pathways. Insect Sci 15(1):29–43
doi: 10.1111/j.1744-7917.2008.00185.x
Kounatidis I, Ligoxygakis P (2012) Drosophila as a model system to unravel the layers of innate immunity to infection. Open Biol 2(5):120075
doi: 10.1098/rsob.120075
Lamoth F, Kontoyiannis DP (2018) The Candida auris alert: facts and perspectives. J Infect Dis 217(4):516–520
doi: 10.1093/infdis/jix597
Rossato L, Colombo AL (2018) Candida auris: what have we learned about its mechanisms of pathogenicity? Front Microbiol 9:3081
doi: 10.3389/fmicb.2018.03081
Enkler L, Richer D, Marchand AL et al (2016) Genome engineering in the yeast pathogen Candida glabrata using the CRISPR-Cas9 system. Sci Rep 6:35766
doi: 10.1038/srep35766
Davis MM, Alvarez FJ, Ryman K et al (2011) Wild-type Drosophila melanogaster as a model host to analyze nitrogen source dependent virulence of Candida albicans. PLoS One 6(11):e27434
doi: 10.1371/journal.pone.0027434
Ben-Ami R, Watson CC, Lewis RE et al (2013) Drosophila melanogaster as a model to explore the effects of methicillin-resistant Staphylococcus aureus strain type on virulence and response to linezolid treatment. Microb Pathog 55:16–20
doi: 10.1016/j.micpath.2012.11.012
Christofi T, Apidianakis Y (2013) Drosophila immune priming against Pseudomonas aeruginosa is short-lasting and depends on cellular and humoral immunity. F1000Res 2:76
doi: 10.12688/f1000research.2-76.v1
de Cássia Orlandi Sardi J, Silva DR, Soares Mendes-Giannini MJ et al (2018) Candida auris: epidemiology, risk factors, virulence, resistance, and therapeutic options. Microb Pathog 125:116–121
doi: 10.1016/j.micpath.2018.09.014
Osei Sekyere J (2018) Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen 7(4):e00578
doi: 10.1002/mbo3.578
Shirazi F, Farmakiotis D, Yan Y et al (2014) Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. PLoS One 9(9):e108635
doi: 10.1371/journal.pone.0108635
Heys C, Lizé A, Blow F et al (2018) The effect of gut microbiota elimination in Drosophila melanogaster: a how-to guide for host-microbiota studies. Ecol Evol 8(8):4150–4161
doi: 10.1002/ece3.3991
Xin H, Mohiuddin F, Tran J et al (2019) Experimental mouse models of disseminated Candida auris infection. mSphere 4(5):e00339-19
doi: 10.1128/mSphere.00339-19
Ben-Ami R, Berman J, Novikov A et al (2017) Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis 23(1):195–203
pmcid: 5324804
CDC Antimicrobial Resistance Isolate Bank. https://www.cdc.gov/drugresistance/resistance-bank/index.html . Last accessed April 28, 2021
Amparan AA, Djoufack-Momo SM, Grunden B et al (2014) Exposure of research personnel to carbon dioxide during euthanasia procedures. J Am Assoc Lab Anim Sci 53(4):376–380
pubmed: 25199093
pmcid: 4113237